→ Modern Healthcare reports that Takeda has been relocating hundreds of R&D jobs out of Chicago and into its big new biotech hub in Boston/Cambridge. According to the report, Takeda has required up to 600 R&D staffers in Chicago to relocate, along with 150 in the vaccines group. Takeda has been shredding its old global R&D structure to favor a concentration of forces in Boston and Japan. But the company, under CEO Christophe Weber and R&D chief Andy Plump, have maintained a considerable air of secrecy in how they’re uprooting groups in an effort to reorganize and create a far more effective biopharma company.
→ Shire has forged a licensing pact with Novimmune for a bi-specific antibody in preclinical development for hemophilia A and hemophilia A patients with inhibitors. No deal terms were disclosed.
→ The UK’s Abzena has granted Telix an exclusive license to its prostate-specific membrane antigen (‘PSMA’) antibodies in the field of radio-immunoconjugation. The PSMA antibodies were created using Abzena’s Composite Human Antibody technology. The deal comes with fees and milestones totaling some $65 million for Abzena.
→ Amgen and Array BioPharma unveiled a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,000+ biopharma pros who read Endpoints News by email every day.Free Subscription